Stockscreener 앱 받기
4.22
1.44%
0.06
시간 외 거래:
4.22
전일 마감가:
$4.16
열려 있는:
$4.15
하루 거래량:
164.70K
Relative Volume:
1.07
시가총액:
$247.77M
수익:
$30.91M
순이익/손실:
$-74.28M
주가수익비율:
-3.4638
EPS:
-1.2183
순현금흐름:
$-86.15M
1주 성능:
+11.35%
1개월 성능:
-21.71%
6개월 성능:
-8.66%
1년 성능:
+1.93%
1일 변동 폭
$4.05
$4.33
1주일 범위
$3.59
$4.33
52주 변동 폭
$3.27
$6.95
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
명칭
Foghorn Therapeutics Inc
전화
617-586-3100
주소
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.22 | 244.25M | 30.91M | -74.28M | -86.15M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 재개 | Jefferies | Buy |
| 2025-12-18 | 개시 | BTIG Research | Buy |
| 2025-11-07 | 개시 | Guggenheim | Buy |
| 2025-09-17 | 재개 | B. Riley Securities | Buy |
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-30 | 개시 | B. Riley Securities | Buy |
| 2024-09-03 | 개시 | Jefferies | Buy |
| 2024-08-19 | 개시 | Evercore ISI | Outperform |
| 2023-03-28 | 개시 | BofA Securities | Buy |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-22 | 개시 | H.C. Wainwright | Buy |
| 2020-11-17 | 개시 | Cowen | Outperform |
| 2020-11-17 | 개시 | Goldman | Buy |
| 2020-11-17 | 개시 | Morgan Stanley | Overweight |
| 2020-11-17 | 개시 | Wedbush | Outperform |
모두보기
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
Foghorn Therapeutics (FHTX) Posts Record Q1 2026 — EPS $-0.29 Blows Past EstimatesLive Trade Sharing - Newser
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
FHTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
BVF entities disclose shares, 6.05M pre‑funded warrants in Foghorn (FHTX) - Stock Titan
EDGAR Filing Documents for 0001628280-25-014475 - SEC.gov
[SCHEDULE 13G/A] Foghorn Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Foghorn Therapeutics discloses new EP300 degradation inducers - BioWorld News
Foghorn Therapeutics schedules trio of investor events to spotlight oncology developments - Traders Union
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - Investing News Network
Foghorn Therapeutics Inc. (FHTX) may report negative earnings: Know the trend ahead of Q1 release - MSN
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report - simplywall.st
The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
FHTX SEC FilingsFoghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Foghorn Therapeutics Inc. (FHTX) reports Q1 loss, lags revenue estimates - MSN
What Foghorn Therapeutics (FHTX) is doing to win in its industry | Q4 2025: Earnings UnderperformSocial Momentum Signals - newser.com
Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update - Investing News Network
Number of shareholders of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Foghorn Therapeutics Highlights Q1 Progress in Oncology Pipeline - TipRanks
Foghorn Therapeutics Inc. 1Q 2026: Revenue $3.3M, EPS $(0.29) — 10-Q Summary - TradingView
Foghorn says lead lung cancer trial stays on track, funded into 2028 - Stock Titan
Foghorn Therapeutics (NASDAQ: FHTX) trims expenses, raises $50M in Q1 2026 - Stock Titan
Foghorn Therapeutics (Nasdaq: FHTX) details Q1 2026 results and oncology pipeline - Stock Titan
FMR LLC reports 11.6% ownership in Foghorn Therapeutics (NASDAQ: FHTX) - Stock Titan
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
The quiet positioning of Foghorn Therapeutics (FHTX) nobody discusses (Market Focus) 2026-05-06Bullish Pattern - Newser
[ARS] Foghorn Therapeutics Inc. SEC Filing - Stock Titan
Executive pay, major holders and votes in Foghorn (NASDAQ: FHTX) 2026 proxy - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 1.9%Time to Sell? - MarketBeat
Stifel reiterates Foghorn Therapeutics stock rating on AACR data By Investing.com - Investing.com Australia
Stifel Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Stifel reiterates Foghorn Therapeutics stock rating on AACR data - Investing.com
Should I sell Foghorn Therapeutics (FHTX) stock today | Q4 2025: Earnings UnderperformExpert Momentum Signals - Xã Châu Thành
H.C. Wainwright reiterates Foghorn Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Foghorn Therapeutics stock rating at buy - Investing.com
Foghorn presents preclinical data for cancer drug candidates By Investing.com - Investing.com South Africa
FHTX Unveils Promising Preclinical Data at AACR Annual Meeting - GuruFocus
Foghorn presents preclinical data for cancer drug candidates - Investing.com
Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR - TipRanks
Foghorn Therapeutics presents new preclinical data on SMARCA2 inhibitor FHD-909 and targeted degrader programs - Traders Union
Foghorn Therapeutics Presents New Preclinical Data for - GlobeNewswire
Foghorn Therapeutics (Nasdaq: FHTX) showcases broad preclinical cancer data and cash runway outlook - Stock Titan
Foghorn Therapeutics Inc (FHTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):